Intravenous citrulline for pain crises in hospitalized people with sickle cell disease
Tests whether intravenous citrulline or a placebo eases pain in hospitalized people with sickle cell.
Key facts
- Who runs it
- Suvankar Majumdar
- Where
- Washington D.C., United StatesSee the site
- Trial code
- Registry title
- Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 99 people, planned
- Started
- 22 Dec 2024
- Expected to end
- Mar 2029
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- L-citrulline
- Placebo
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with sickle cell disease who are in hospital with a pain episode and need strong pain medicine through a vein or injection.
- Age
- 4 to 21 years
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease of any genotype, with a vaso-occlusive pain episode that needs hospital care and parenteral opioid treatment. The first dose of study drug or placebo must be possible within 12 hours of the first parenteral opioid dose in the Emergency Department.
- Earlier treatment
- People using L-glutamine cannot join. People with a medical regimen needing daily opioids cannot join.
Main reasons for not taking part
- Pain lasting more than 3 days
- More than 9 hospital stays in the past year
- Another sickle cell complication needing the hospital stay, such as stroke or splenic sequestration
- History of opioid use disorder or chronic pain
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Sickle cell disease (all genotypes)
- Patients with sickle cell disease ages 4 to 21 years old
- Presence of sickle cell vaso-occlusive pain episode requiring hospitalization and parenteral opioid therapy
- Able to randomize to study drug/placebo within 12 hours of first dose of parenteral opioid in the Emergency Department
Who cannot take part
- >9 hospitalizations in the prior year
- Presence of any other complication related to sickle cell disease requiring the hospitalization such as splenic sequestration, hepatic sequestration, stroke, transient ischemic attack, etc
- History of opioid use disorder, chronic pain or medical regimen requiring daily opioid use
- Presence of acute chest syndrome, sepsis, bacterial infection, hemodynamic instability
- History of allergic reaction to L-citrulline products
- Severe anemia (hemoglobin <6g/dL)
- Alanine/aspartate transferase >2x upper limit of normal laboratory range for age
- Subject has the following serum creatinine:; Age 4 to 13 years > 0.9 mg/dL; Age 14 to 17 years 1.0 mg/dL; Age ≥18 years >1.5mg/dL
- Current pain lasting >3 days
- Pregnant (as confirmed by a positive urine pregnancy test) or lactating female
- Use of L-glutamine
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 4 and 21 years old?
Where in United States
- Children's National HospitalWashington D.C., United StatesContact: Jillian Baker, RNTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are:
Read full original descriptionShow less
* Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization * What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain.
Participants will:
* Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay * After hospital discharge, visit the clinic in about 30 days for checkup and tests
The 3 groups in the trial
- Low dose intravenous L-citrullineTreatment being tested
Treatment: L-citrulline
- High dose intravenous L-citrullineTreatment being tested
Treatment: L-citrulline
- PlaceboPlacebo, for comparison
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Randomized Double-blind, Placebo-controlled Clinical Trial of Intravenous Citrulline for Vaso-occlusive Pain Episode in Hospitalized Patients With Sickle Cell Disease (CONQUER SCD Pain Trial)
- Plain-language title
- Intravenous citrulline for pain crises in hospitalized people with sickle cell diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06635902, who can take part
- Record updated
- 13 April 2026